OPENAI has announced the development of the GPT-4B Micro model in collaboration with Retro Biosciences, aimed at posting the limits of biology and cell reprogramming. Although promising, this model still requires scientific validations before confirming its effectiveness and impact on human science and longevity.
Sam Altman announces ” unexpected scientific results »Thanks to AI
OPENAI announces that it has formed a new model of artificial intelligence (AI) called “GPT-4B Micro” with the Longevity Startup Retro Biosciences.
Since the late 1960s, biology researchers have been interested in the crucial role of molecules in the processes essential to life. It was only from 2020 that an IA software developed by Google Deepmind, named Alphafold, begins to provide answers.
It is the now very famous Openia's turn to enter the game of science and to push the limits of what human beings have accomplished for the time being.
🌐 Discovery – What is AI16Z, the investment fund propelled by an AI agent?
In all areas, proteins seem better than scientists have been able to produce by themselves
.
Last week, the CEO of Openai, Sam Altman, said for the first time publicly having obtained ” unexpected scientific results »Thanks to an AI model based on biological data. This announcement represents a major step on the path of ” general artificial intelligence ».
Super intelligent tools could massively accelerate scientific discovery and innovation far beyond what we are capable of doing by ourselves
.
Open an account on N26, the crypto-friendly bank
GPT-4B Micro: a new border in cell reprogramming
Retro Biosciences aims to extend normal human life by 10 years. To do so, the latter studies what is called the Yamanka factors. It is in fact a set of proteins capable of reprogramming a human skin cell in a young stem cell.
These cells have the ability to differentiate themselves into any type of specific cell of the human body, such as muscle, nervous, or even cardiac cells. This property makes them essential to regenerate damaged tissues, create replacement organs or develop new treatments against degenerative diseases.
✅ In the news – Nvidia reveals its ambitions for 2025: physical, robotics, autonomous cars and gaming
The precise functioning of the GPT-4B and the way in which it reaches its conclusions remain vague, a common phenomenon with the models of AI. “” It's a bit like Alphago, who beat the best Go player: it took time to understand why “Explains Joe Betts-Lacroix, the director general of Retro Biosciences.
We are still discovering what this model can really do, and we think that we are only a tiny part.
However, today, this technique of ” reprogramming cellular »Remains ineffectiverequiring several weeks to achieve a result, with less than 1 % of the treated cells reaching the final rejuvenation stage in a laboratory.
In addition, the model is not yet accessible for wider use: there remains a demonstration to prove the seriousness of this contribution to science and not an official launch of product, recalls Aaron Jaech, one of the main developers of the GPT-4B microphone model.
External scientists will have to wait for the publication of the results, this transparency stage is essential to allow independent validation and guarantee that the results are not based on biases or errors. Without this validation, the announcements remain for the moment promises awaiting concrete evidence.
Zengo: the ultra-secure mobile wallet for your BTC
Source: MIT Technology Review
The crypto newsletter n ° 1 🍞
Receive a summary of crypto news every day by email 👌
Certain links present in this article may be affiliated. This means that if you buy a product or register on a site from this article, our partner gives us a commission.
Investments in cryptocurrencies are risky. There is no guaranteed high yield, a product with high performance potential implies a high risk. This risk taking must be in line with your project, your investment horizon and your ability to lose part of this savings. Do not invest if you are not ready to lose all or part of your capital